866-997-4948(US-Canada Toll Free)

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Aug 2017

Category :

Pharmaceutical

No. of Pages : 47 Pages

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Pipeline Review, H2 2017

Summary

According to the recently published report 'T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3Leu 4 Epsilon Chain or CD3E) - Pipeline Review, H2 2017'; T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - T-Cell surface glycoprotein CD3 epsilon chain also known as CD3E is a polypeptide encoded by the CD3E gene. T-cell surface glycoprotein CD3 epsilon chain interacts with TOP2B, CD3EAPand NCK2. The CD3 complex mediates signal transduction, resulting in T-cell activation and proliferation.

The report 'T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3Leu 4 Epsilon Chain or CD3E) - Pipeline Review, H2 2017' outlays comprehensive information on the T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 3 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Metabolic Disorders, Central Nervous System, Gastrointestinal and Infectious Disease which include indications Type 1 Diabetes (Juvenile Diabetes), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Autoimmune Disorders, Chronic Inflammation, Crohn's Disease (Regional Enteritis), Hepatitis B, Inflammatory Bowel Disease, Kidney Transplant Rejection, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Non-Alcoholic Steatohepatitis (NASH), Primary Biliary Cirrhosis, Psoriasis and Rheumatoid Arthritis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)
- The report reviews T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics and enlists all their major and minor projects
- The report assesses T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Overview 6
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 10
Products under Development by Universities/Institutes 12
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Therapeutics Assessment 14
Assessment by Mechanism of Action 14
Assessment by Route of Administration 16
Assessment by Molecule Type 18
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Companies Involved in Therapeutics Development 20
Amgen Inc 20
GlaxoSmithKline Plc 20
MacroGenics Inc 21
Numab Innovation AG 21
SYNIMMUNE GmbH 22
Tiziana Life Sciences Plc 22
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Drug Profiles 23
Bispecific Monoclonal Antibodies to Target CD3, CD16 and HBsAg for HBV Infection and Oncology - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
foralumab - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
ND-007 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
otelixizumab - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
TACSYN - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
teplizumab - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
XmAb-13551 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Dormant Products 34
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Product Development Milestones 35
Featured News & Press Releases 35
Jul 28, 2017: Publication of Research Article on Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases 35
Mar 14, 2017: Tiziana Life Sciences Appoints Dr. Arun Sanyal to its Scientific Advisory Board 35
Nov 18, 2016: New Publication: Partial Exhaustion of CD8 T Cells in Responders to Anti-CD3 Treatment in New-Onset Type 1 Diabetes 36
Nov 16, 2016: Tiziana Life Sciences Announces New Data with Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases 36
May 19, 2016: Immunotherapy Journal Review of Anti - CD3 Monoclonal Antibodies Highlights Therapeutic Potential of Tizianas Foralumab 37
Jan 11, 2016: Tiziana announces plans for clinical development of foralumab, the company fully human CD3 antibody 38
Jun 28, 2011: MacroGenics Announces Publication Of Protege Phase III Clinical Data Of Teplizumab In The Lancet 38
Jun 23, 2011: MacroGenics To Present Protege Phase III Clinical Data Of Teplizumab In Type 1 Diabetes At ADA In San Diego, US 39
Mar 11, 2011: Tolerx And GSK Announce Phase III Defend-1 Study Of Otelixizumab In Type 1 Diabetes Fails Primary Endpoint 40
Oct 20, 2010: MacroGenics And Lilly Report Pivotal Clinical Trial Of Teplizumab Did Not Meet Primary Efficacy Endpoint 40
Sep 23, 2010: Tolerx Enrolls First Patient In Europe In DEFEND-2 Phase III Clinical Study For Treatment Of Type 1 Diabetes 41
Sep 23, 2010: Tolerx Presents Baseline Data From DEFEND-1 Study At European Association For Study Of Diabetes Annual Meeting 42
Jun 28, 2010: Tolerx Initiates Confirmatory Phase III Trial With Otelixizumab For Type 1 Diabetes 43
Jun 28, 2010: Tolerx Presents Baseline Data From DEFEND-1 Study Validating C-Peptide As Critical Clinical Measure For New-Onset Type 1 Diabetes 44
Mar 17, 2010: Single Short Course of Tolerx's Otelixizumab Provides Prolonged Preservation Of Beta Cell Function 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47

List of Tables
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Indication, H2 2017 9
Number of Products under Development by Companies, H2 2017 10
Products under Development by Companies, H2 2017 11
Number of Products under Investigation by Universities/Institutes, H2 2017 12
Products under Investigation by Universities/Institutes, H2 2017 13
Number of Products by Stage and Mechanism of Actions, H2 2017 15
Number of Products by Stage and Route of Administration, H2 2017 17
Number of Products by Stage and Molecule Type, H2 2017 19
Pipeline by Amgen Inc, H2 2017 20
Pipeline by GlaxoSmithKline Plc, H2 2017 20
Pipeline by MacroGenics Inc, H2 2017 21
Pipeline by Numab Innovation AG, H2 2017 21
Pipeline by SYNIMMUNE GmbH, H2 2017 22
Pipeline by Tiziana Life Sciences Plc, H2 2017 22
Dormant Projects, H2 2017 34

List of Figures
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Top 10 Indications, H2 2017 9
Number of Products by Mechanism of Actions, H2 2017 14
Number of Products by Stage and Mechanism of Actions, H2 2017 14
Number of Products by Routes of Administration, H2 2017 16
Number of Products by Stage and Routes of Administration, H2 2017 16
Number of Products by Molecule Types, H2 2017 18
Number of Products by Stage and Molecule Types, H2 2017 18

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *